Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003103216 | Prostate | Tumor | actomyosin structure organization | 63/3246 | 196/18723 | 2.94e-07 | 6.72e-06 | 63 |
GO:003223118 | Prostate | Tumor | regulation of actin filament bundle assembly | 40/3246 | 105/18723 | 3.34e-07 | 7.55e-06 | 40 |
GO:003432915 | Prostate | Tumor | cell junction assembly | 113/3246 | 420/18723 | 4.94e-07 | 1.07e-05 | 113 |
GO:003367417 | Prostate | Tumor | positive regulation of kinase activity | 123/3246 | 467/18723 | 5.36e-07 | 1.15e-05 | 123 |
GO:011002019 | Prostate | Tumor | regulation of actomyosin structure organization | 38/3246 | 100/18723 | 7.01e-07 | 1.42e-05 | 38 |
GO:004586015 | Prostate | Tumor | positive regulation of protein kinase activity | 105/3246 | 386/18723 | 7.09e-07 | 1.43e-05 | 105 |
GO:200123815 | Prostate | Tumor | positive regulation of extrinsic apoptotic signaling pathway | 23/3246 | 48/18723 | 1.02e-06 | 1.96e-05 | 23 |
GO:003003818 | Prostate | Tumor | contractile actin filament bundle assembly | 39/3246 | 106/18723 | 1.31e-06 | 2.39e-05 | 39 |
GO:004314918 | Prostate | Tumor | stress fiber assembly | 39/3246 | 106/18723 | 1.31e-06 | 2.39e-05 | 39 |
GO:005149219 | Prostate | Tumor | regulation of stress fiber assembly | 35/3246 | 91/18723 | 1.37e-06 | 2.49e-05 | 35 |
GO:001635814 | Prostate | Tumor | dendrite development | 72/3246 | 243/18723 | 1.44e-06 | 2.59e-05 | 72 |
GO:006099613 | Prostate | Tumor | dendritic spine development | 37/3246 | 99/18723 | 1.57e-06 | 2.79e-05 | 37 |
GO:190290416 | Prostate | Tumor | negative regulation of supramolecular fiber organization | 54/3246 | 167/18723 | 1.64e-06 | 2.90e-05 | 54 |
GO:003367316 | Prostate | Tumor | negative regulation of kinase activity | 70/3246 | 237/18723 | 2.27e-06 | 3.87e-05 | 70 |
GO:001097514 | Prostate | Tumor | regulation of neuron projection development | 115/3246 | 445/18723 | 3.34e-06 | 5.44e-05 | 115 |
GO:000646917 | Prostate | Tumor | negative regulation of protein kinase activity | 63/3246 | 212/18723 | 5.73e-06 | 8.78e-05 | 63 |
GO:200011717 | Prostate | Tumor | negative regulation of cysteine-type endopeptidase activity | 32/3246 | 86/18723 | 8.65e-06 | 1.27e-04 | 32 |
GO:004521617 | Prostate | Tumor | cell-cell junction organization | 59/3246 | 200/18723 | 1.43e-05 | 1.94e-04 | 59 |
GO:004315416 | Prostate | Tumor | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 29/3246 | 78/18723 | 2.29e-05 | 2.88e-04 | 29 |
GO:005134617 | Prostate | Tumor | negative regulation of hydrolase activity | 97/3246 | 379/18723 | 2.87e-05 | 3.46e-04 | 97 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0513024 | Breast | IDC | Pathogenic Escherichia coli infection | 42/867 | 197/8465 | 2.66e-06 | 3.92e-05 | 2.94e-05 | 42 |
hsa0481014 | Breast | IDC | Regulation of actin cytoskeleton | 36/867 | 229/8465 | 5.79e-03 | 3.13e-02 | 2.34e-02 | 36 |
hsa045109 | Breast | IDC | Focal adhesion | 32/867 | 203/8465 | 8.60e-03 | 4.23e-02 | 3.17e-02 | 32 |
hsa052118 | Breast | IDC | Renal cell carcinoma | 14/867 | 69/8465 | 9.16e-03 | 4.37e-02 | 3.27e-02 | 14 |
hsa0517014 | Breast | IDC | Human immunodeficiency virus 1 infection | 33/867 | 212/8465 | 9.28e-03 | 4.37e-02 | 3.27e-02 | 33 |
hsa0513034 | Breast | IDC | Pathogenic Escherichia coli infection | 42/867 | 197/8465 | 2.66e-06 | 3.92e-05 | 2.94e-05 | 42 |
hsa0481015 | Breast | IDC | Regulation of actin cytoskeleton | 36/867 | 229/8465 | 5.79e-03 | 3.13e-02 | 2.34e-02 | 36 |
hsa0451013 | Breast | IDC | Focal adhesion | 32/867 | 203/8465 | 8.60e-03 | 4.23e-02 | 3.17e-02 | 32 |
hsa0521113 | Breast | IDC | Renal cell carcinoma | 14/867 | 69/8465 | 9.16e-03 | 4.37e-02 | 3.27e-02 | 14 |
hsa0517015 | Breast | IDC | Human immunodeficiency virus 1 infection | 33/867 | 212/8465 | 9.28e-03 | 4.37e-02 | 3.27e-02 | 33 |
hsa0513043 | Breast | DCIS | Pathogenic Escherichia coli infection | 42/846 | 197/8465 | 1.40e-06 | 2.15e-05 | 1.59e-05 | 42 |
hsa0517024 | Breast | DCIS | Human immunodeficiency virus 1 infection | 33/846 | 212/8465 | 6.49e-03 | 3.22e-02 | 2.37e-02 | 33 |
hsa0481023 | Breast | DCIS | Regulation of actin cytoskeleton | 35/846 | 229/8465 | 6.89e-03 | 3.37e-02 | 2.48e-02 | 35 |
hsa0521123 | Breast | DCIS | Renal cell carcinoma | 14/846 | 69/8465 | 7.42e-03 | 3.48e-02 | 2.56e-02 | 14 |
hsa0513053 | Breast | DCIS | Pathogenic Escherichia coli infection | 42/846 | 197/8465 | 1.40e-06 | 2.15e-05 | 1.59e-05 | 42 |
hsa0517034 | Breast | DCIS | Human immunodeficiency virus 1 infection | 33/846 | 212/8465 | 6.49e-03 | 3.22e-02 | 2.37e-02 | 33 |
hsa0481033 | Breast | DCIS | Regulation of actin cytoskeleton | 35/846 | 229/8465 | 6.89e-03 | 3.37e-02 | 2.48e-02 | 35 |
hsa0521133 | Breast | DCIS | Renal cell carcinoma | 14/846 | 69/8465 | 7.42e-03 | 3.48e-02 | 2.56e-02 | 14 |
hsa0513020 | Cervix | CC | Pathogenic Escherichia coli infection | 63/1267 | 197/8465 | 9.28e-10 | 2.00e-08 | 1.19e-08 | 63 |
hsa0451010 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PAK2 | SNV | Missense_Mutation | | c.1312G>A | p.Glu438Lys | p.E438K | Q13177 | protein_coding | deleterious(0.02) | probably_damaging(0.995) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
PAK2 | SNV | Missense_Mutation | | c.1336N>A | p.Glu446Lys | p.E446K | Q13177 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
PAK2 | SNV | Missense_Mutation | | c.103N>G | p.His35Asp | p.H35D | Q13177 | protein_coding | tolerated(0.19) | benign(0.003) | TCGA-AN-A0XN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
PAK2 | SNV | Missense_Mutation | | c.419N>C | p.Leu140Pro | p.L140P | Q13177 | protein_coding | tolerated(0.08) | possibly_damaging(0.62) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PAK2 | SNV | Missense_Mutation | novel | c.241G>A | p.Glu81Lys | p.E81K | Q13177 | protein_coding | tolerated(0.35) | possibly_damaging(0.734) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PAK2 | SNV | Missense_Mutation | rs774110601 | c.1250N>A | p.Arg417Gln | p.R417Q | Q13177 | protein_coding | tolerated(0.11) | probably_damaging(0.993) | TCGA-E9-A295-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
PAK2 | insertion | In_Frame_Ins | novel | c.627_628insTCTCGCTCTGTCGCC | p.Ser209_His210insSerArgSerValAla | p.S209_H210insSRSVA | Q13177 | protein_coding | | | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
PAK2 | insertion | Frame_Shift_Ins | novel | c.566_567insAAGAAGCAAACTTTTTGAAG | p.His189GlnfsTer17 | p.H189Qfs*17 | Q13177 | protein_coding | | | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
PAK2 | insertion | Frame_Shift_Ins | novel | c.570_571insTTCATAAAGGGCGATAGTCG | p.Lys191PhefsTer15 | p.K191Ffs*15 | Q13177 | protein_coding | | | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
PAK2 | insertion | Nonsense_Mutation | novel | c.746_747insATGATACACAGTCATTGCTAACAACTAGTACAGTT | p.Tyr249Ter | p.Y249* | Q13177 | protein_coding | | | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5062 | PAK2 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | 310264720 | | |
5062 | PAK2 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | 249565812 | | |
5062 | PAK2 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | 310264719 | | |
5062 | PAK2 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | 329968394 | | |
5062 | PAK2 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | allosteric modulator | 310264717 | | |
5062 | PAK2 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | 310264722 | | |
5062 | PAK2 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | 310264718 | PF-03758309 | |
5062 | PAK2 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | 135652717 | STAUROSPORINE | |